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Summary 
Platelet are key players in haemostasis and represent a pivotal link between 
inflammation, immunity and atherogenesis. Cysteinyl leukotrienes (CysLTs)  
such as LTC4, LTD4, and LTE4 are potent lipid inflammatory mediators which 
interact with G protein-coupled receptors, CysLT1R, CysLT2R .  However, LTE4, 
the most stable cystenyl leukotriene, is not putative substrate for these two 
receptor. Recently have been hypothesized that a third cystenyl leukotreine 
receptor exists, and a computer modeling suggests P2Y12, receptor for ADP 
present on platelet surface, as the putative receptor. But GPR99 is also 
hypothesized as LTE4 putative receptor. It is known that LTE4 needs P2Y12 on 
platelet to mediate inflammation in sensitized mice, and LTC4 can induce 
release of P-selectin in sensitized mice. In human platelet LTE4 cannot increase 
level of cAMP, or of p-selectin.  
Aim of this study was to test whether cystenyl leukotrienes elicit platelet 
functional responses, by interacting with the platelet P2Y12, receptor for ADP. 
 We measure the platelet aggregation induced by CysLTs alone or in 
combination with epinephrine or ADP; the cAMP level in presence of PGE1, 
ADP and CysLTs, and finally the p-selectin expression on platelet surface after 
stimulation with ADP and CysLTs and in presence/absence of cangrelor. 
Ours results shows that CysLTs cannot affect platelet aggregation alone or in 
combination with other agonist, independently of  presence of physiological  
level of calcium. 
CysLTs failed to show an effect also on cAMP level. Also when platelet 
activation was tested by measuring the expression of p-selectin on the platelet 
membrane induced by ADP, CysLTs failed to show any effect. 
The negative results of our studies are not due to alterations of the CysLTs that 
we used, as they were identified correctly at mass spectrometry and induced 
normal cellular response of HUVEC, as previously shown. The inflammatory 
effects of CysLTs mediated by the platelet P2Y12 receptor, which have been 
demonstrated in vivo experiments, were most likely indirect, rather than induced 
by a direct interaction of CysLTs with platelets. 
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1.1 CYSTENYL LEUKOTRIENES 
1.1.1 Leukotrienes : structure and biosynthesis 
Leukotrienes are a family members of eicosanoid inflammatory mediators 
produced by immunocompetent cells starting from arachidonic acid [1]. The 
name leukotriene, introduced by the swedish biochemist Bengt Samuelsson in 
1979, comes from the word leukocyte, where they were first discovered, and 
triene (indicating the compound's three conjugated double bonds). Leukotriene 
family consists of five molecules: LTA4, LTB4, LTC4, LTD4, LTE4. The latter 
three are collectively known as “cysteinyl leukotrienes (cysLTs)” due to the 
presence of cysteine amino acid in their structures.[2] 
LTC4                       
 
LTD4  
 
 
LTE4 
 
Figure 1.1 cysteinyl leukotrienes LTC4, LTD4, LTE4. 
 
The leukotriene synthesis pathway starts from the release of arachidonic acid 
from the perinuclear phospholipid membrane, endoplasmic reticulum, and/or 
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Golgi apparatus by activation of cytosolic phospholipase (cPL) A2α [3]. 
Arachidonic acid is then converted into LTA4 through the enzyme of 5-
lipoxygenase (5-LO). The lipoxygenase pathway is active in leukocytes 
(eosinophils, neutrophils, monocytes, and basophils) and other 
immunocompetent cells (mast cells, macrophages, myeloid dendritic cells). 
LTA4 can be converted either into LTB4 by the LTA4 hydrolase (LTA4H) or into 
LTC4 by LTC4 synthase (LTC4S) (Figure2).  
Once synthesized, LTB4 and LTC4 are exported from the cell by two members 
of the multidrug resistance-associated protein (MRP) transporter family, MRP4 
and MRP1, respectively [4]. All members of this proteins family mediates the 
efflux transport of amphipathic anions from the cell (e.g. signaling molecules, 
uric acid, eicosanoids) and also have an affinity for several drugs, including 
anticancer and antiviral agents  as well as nucleoside analogues [5]. LTC4 is 
then converted into LTD4 by the actions of γ-glutamyl transferase, which 
removes the glutamate residue from glutathione [6]. LTD4 is in turn converted to 
LTE4 by dipeptidase, which removes the glycine residue [2].  
Very few cells express the three key enzymes for the whole leukotriene 
synthesis (5-LO, LTA4H, LTC4S). This indicates that in vivo leukotriene 
biosynthesis involves cooperation between multiple cell types. Neutrophils, the 
primary source of LTA4 generation, do not express LTC4S [7, 8], which is 
expressed in eosinophils, mast cells, monocytes, and macrophages. Red blood 
cells which do not express 5-LO and cannot produce LTA4, are capable to 
convert exogenous LTA4 into LTB4, as shown by in vitro experiments[9, 10], as 
well as platelets[11] [7] which express LTC4S and release LTC4. [7, 12]. 
 
LTC4 and LTD4 have been considered the only active cysLTs, exert their effects 
locally following secretion. As their short half-lives, LTE4 is the most stable LTs, 
but to date data about its biological effects are contradictory  [13, 14]. 
The biological action of cysLT are mediated by two receptor discusses  in next 
paragraph. 
8 
 
 
Figure 1.2 : Schematic figure of leukotriene biosynthesis. Increases in intracellular 
calcium concentrations promotes the translocation of cPLA2α  to the nuclear 
membrane, this process liberates arachidonic acid (AA) from the phospholipid bilayer 
and presents it to 5-LO, which converts it to leukotriene A4 (LTA4). LTA4 is then 
converted into either leukotriene B4 (LTB4) by LTA4 hydrolase (LTA4H) present in the 
cytosol or to leukotriene C4 by LTC4 synthase(LTC4S), at the nuclear membrane. LTB4 
and LTC4 are exported from the cell by multidrug-resistance proteins (MRPs) 4 and 1, 
respectively. LTC4 can also be converted to leukotriene D4 (LTD4), which also binds to 
CysLT1R and CysLT2R, by γ-glutamyl transferase (GGT). Finally, LTD4 is converted to 
the stable metabolite leukotriene E4 (LTE4). 
 
 
1.1.2 Leuokotrienes activity 
Cysteinyl leukotrienes are very potent lipid inflammatory mediators, they induce 
smooth muscle constriction that is very well studied, and as a result, anti-
leukotriene pharmacological agents have become a popular asthma treatment 
option [15, 16] CysLTs also affect vascular smooth muscle, and can elicit 
vasoconstriction in both arteries and veins [17, 18]. Interestingly, CysLTs have 
been shown to induce vasoconstriction in atherosclerotic coronary arteries, but 
not in healthy people [19]- indicating that pathogenesis may increase the scale 
and severity of leukotriene-mediated responses. CysLTs also exert effects on 
circulating cells and on endothelial cells. CysLT stimulation induces chemotaxis 
9 
 
of monocytes [20] [21], eosinophils [22], dendritic cells [23] and CD34+ 
progenitor cells [24, 25]. CysLT stimulation also upregulates Mac-1 in 
eosinophils [22], promotes proliferation in CD34+ progenitor cells [26], and 
induces release of the chemokine RANTES from platelets [27]. LTC4 and LTD4 
stimulation of endothelial cells in vitro results in production of PAF, promotion of 
neutrophil adhesion [28],  secretion of von Willebrand factor, and surface 
expression of p-selectin [29]. In addition, CysLT stimulation triggers vascular 
hyperpermeability in multiple vascular beds [2, 30, 31]. CysLTs have also been 
implicated with an important role in host defense, as attenuated leukotriene 
synthesis has been linked to increased susceptibility to infectious disease in 
both humans and animal models [32]. 
While LTE4 received its fair share of attention following its discovery, its poor 
affinity for the classical CysLT receptors resulted in its fading from the spotlight. 
However, early studies noted that LTE4 potency was 10-fold greater than that of 
LTC4 or LTD4 in guinea pig trachea [33]. LTE4 was also distinct in its ability to 
augment contractile response to histamine, something that LTC4 or LTD4 
stimulation could not do [34]. LTE4 was also found to induce vascular 
permeability with equal potency as LTC4 or LTD4 when injected intradermally in 
humans [35]. These findings suggest that LTE4 either uniquely mediates 
pathways that LTC4 or LTD4 do not, or that there are receptors that favor LTE4 
as a ligand over LTC4 and LTD4. 
 
 1.1.3 Cysteinyl leukotrienes receptors 
Cysteinyl leukotrienes bind two G-protein coupled receptors, named cysteinyl 
leukotriene receptor 1 (CysLT1R) and cysteinyl leukotriene receptor 2 
(CysLT2R). Further investigation yielded a receptor favouring leukotriene E4 
rather than C4 and/or D4[36]. However, until now the two most investigated 
receptors remains CysLT1R and CysLT2R.  
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 CysLT1R 
The human CysLT1R  was first characterized in 1999 by two separate groups. It 
is a 337 amino acid G-protein coupled receptor that signals predominantly 
through Gq/11 class G proteins, although it does show limited activation of Gi/0 
pathways [37, 38]. The human CysLT1R shares only 38% homology with the 
human CysLT2R, and is actually more similar to the purinergic receptor P2Y1 
(32% homology)[37-39]  
Activation of CysLT1R results in mobilization of intracellular Ca
2+ via both Gq/11 
and Gi/o pathway activation [37, 40].  Induction of proliferation has been 
observed in numerous cell line following CysLT1R activation, including human 
hematopoietic cells [26] epithelial cells [41, 42], smooth muscle cells [43, 44], 
and astrocytes [45, 46]. In addition, CysLT1R activation upregulates pro-
inflammatory mediators, including β-integrins [25, 47], IL-4[48] , IL-5[27, 49, 50] 
,  IL-8[51] , IL-11[52], TGF-β1[53] , as well as MIP-1α and MIP-1β [54], Finally, 
CysLTR pharmacological blockade results in decreased of IL-4, IL-5, IL-8, IL-
11, IL-13, TNFα, RANTES, and TGF-β [52, 55-57] 
 
 CysLT2R 
The human CysLT2R was first characterized in 2000 by three independent 
groups [39, 58, 59] It is a 346 aa protein that shares 33% homology with the 
orphan receptor GPR17 (and as mentioned before, only 38% homology with 
CysLT1R)[39]. The human CysLT2R expression profile is distinct from that of 
CysLT1R, being found predominantly in the heart (expressed in atria, ventricles, 
and Purkinje fibers - but not the aorta), spleen, brain, lymphatic system, 
placenta, and adrenal gland [39, 58, 59]; Indeed, it is the dominant cysLT 
receptor in heart and brain[58] and unlike CysLT1R, is not found high 
abundance in the lung [39]. CysLT2R is also expressed by numerous circulating 
cells, including eosinophils [60],  monocytes, macrophages[39] , mast cells [61]  
and platelets [27] , but not neutrophils [62]. It is also expressed in HUVECs 
[63]and coronary artery SMCs [64] . 
CysLT2R activation results in altered endothelial cell function, as well as 
cytokine secretion. Activation of CysLT2R in HUVECs leads to increased 
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intracellular calcium concentration, myosin light chain kinase activation [63, 65], 
P-selectin surface expression [66], and the up regulation of a myriad of pro-
inflammatory genes including CXCL2 (which encodes the MIP-2α protein), 
SELE (E-selectin), IL-8, EGR1, and PTGS2 [67]. In human mast cells, CysLT2R 
activation facilitates IL-8 secretion, but through a pertussis toxin-sensitive 
pathway [61] 
 
 Other CysLT receptors  
In addition to CysLT1R and CysLT2R, data has implicated CysLT activation of 
other GPCRs. A possible third cysLT receptor was first proposed after [68]  
noted that IL-4 treatment in mast cells upregulated two receptors: CysLT1R and 
a receptor that could not be CysLT2R based on pharmacological antagonism 
experiments. Moreover, these cells responded to both cysLTs and UDP, and as 
CysLT1R activation by UDP was later ruled out[69, 70]. Further investigation 
revealed that GPR17, a receptor structrually and phylogenetically related to 
other P2Y receptors and CysLT receptors[71], could be activated in a specific 
and dose-dependent manner by both cysLTs and uracil nucleotides [71, 72].  
Nonaka et al. [73] used a computer model to determine that LTE4 is a potential 
ligand for P2Y12 
Of the cysteinyl leukotrienes (LTs; LTC4, LTD4, and LTE4), only LTE4 is stable 
and abundant in vivo and it’s shows negligible activity at CysLT1R and CysLT2R  
[14]shown that the adenosine diphosphate (ADP)–reactive purinergic (P2Y12) 
receptor is required for LTE4-mediated pulmonary inflammation. This effect, in 
mice, is mediated by P2Y12 receptor on platelets[14]. There is no evidence of a 
direct binding between LTs and P2Y12. 
Another receptor has been recently identified as GPR99 [36]. The LTE4-
mediated ear edema observed in CysLT1R/CysLT2R double knockout mice was 
almost completely abolished in GPR99/CysLT1R/CysLT2R triple knockout mice. 
Stimulation with LTC4 or LTD4 did elicit a mild response in CysLT1R/CysLT2R 
double knockout mice, indicating that GPR99 can bind LTC44 or LTD4 in the 
absence of the classical cysLT receptors[36]  
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1.2 PLATELETS 
1.2.1 Platelet biology 
Platelets are small anucleate blood cells, with a discoid shape ranging between 
1 to 3 µm in diameter. These cell fragments originate from the cytoplasm of 
megakaryocytes (MKs) in the bone marrow and circulate in the human 
bloodstream for about 10 days. Platelets lack genomic DNA [74] but contain 
megakaryocyte-derived messenger RNA (mRNA) and the translational 
machinery needed for protein synthesis including ribosomes, and initiation and 
termination factors [75]. Furthermore, platelets contain three types of secretory 
organelles known as α-granules, δ-granules (dense) and lysosomes, which are 
generated by the budding of small vesicles containing granule cargo from the 
trans-Golgi zone of the Golgi complex in MKs [76]. The number of α-granules 
per platelet depends on cell size but and may range between 40 and 80. They 
contain many proteins, such as coagulation factor V, thrombospondin, P-
selectin, von Willebrand Factor (vWF) and fibrinogen. The δ-granules, 
compared with α-granules, are smaller, fewer, and have high morphological 
variability. They are rich in ATP and ADP, serotonin, pyrophosphate, calcium, 
and magnesium. Human platelets also contain few lysosomes (no more than 3), 
which contain at least 13 acid hydrolases. Other organelles present in the 
platelet cytoplasm include a small number of simple mitochondria involved in 
energy metabolism, glycosomes [77], electron dense chains and clusters [78], 
and tubular inclusions [79].  
 
 
1.2.2 Platelets in primary haemostasis 
The main role of blood platelets is to ensure primary haemostasis, which means 
the rapid cessation of bleeding after tissue trauma and the maintenance of the 
integrity of the endothelium, in part through the release of proangiogenic 
cytokines and growth factors. The balance between blood fluidity and rapid 
thrombus formation in response to injury is regulated by endothelial cells, which 
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synthesize either inhibitors or activators of platelet aggregation and blood 
clotting [80, 81]. Under normal physiological conditions, platelets circulate close 
to the endothelium without establishing/ forming stable adhesion contacts. The 
anti-adhesive phenotype of vascular endothelium cells towards platelet is 
maintained by at least 4 intrinsic pathways. The arachidonic acid-prostacyclin 
(PGI2) and the L-arginine-nitric oxide (NO) pathways inhibit platelet activation by 
the stimulation of cAMP and cGMP production respectively, whereas 
endothelial ecto-adenosine diphosphatase (ecto-ADPase/CD39) is involved in 
ADP metabolism, which is necessary to prevent premature platelet activation at 
the vessel wall. Furthermore, thrombomodulin rapidly inhibits the prothrombotic 
effect of α thrombin, reducing platelet activation and fibrin generation (Figure 2).  
 
At sites of vascular injury, platelets interact with the damaged vessel, to form a 
platelet aggregate. The initial platelet tethering at the surface and subsequent 
platelet-platelet cohesion are typically differentiated into the following  steps: 
adhesion, activation, secretion and aggregation of platelets [82].  
 
 Platelet Adhesion 
After vascular injury, such as rupture or erosion of the vessel wall, 
subendothelial matrix proteins such as collagen, von Willebrand factor (vWF), 
fibronectin and laminin become exposed to the circulating blood. These proteins 
support platelet adhesion via the engagement of specific receptors, thus rapidly 
recruiting individual platelets at the site of subendothelial damage. The initial 
tethering of platelets occurs via the interaction between glycoprotein Ib (GPIb), 
a component of GPIb-V-IX platelet complex, and exposed collagen-bound vWF. 
This bond has a rapid dissociation rate and is therefore unable to support stable 
adhesion, resulting in platelet translocation along the vessel wall. Translocating 
platelets engage with collagen in the vessel wall through their adhesion 
receptors glycoprotein VI (GPVI) and GPIa. GPVI is the major collagen 
receptor, whose stimulation induces the intracellular calcium flux necessary for 
stable platelet adhesion, cytoskeletal reorganization, integrin glycoprotein 
IIb/IIIa (αIIbβ3) activation and the release of soluble agonists.  
14 
 
 
 Platelet Activation and Secretion 
After the initial adhesion, platelets undergo the repair process that requires a 
quick response to autocrine and paracrine mediators. Platelets experience a 
complex series of morphological and biochemical changes that lead to the 
release of platelet granular content such as ADP and serotonin (5-HT), as well 
as to the synthesis of TxA2. These endogenous agonists act to enhance platelet 
activation by interacting with specific G-protein coupled receptors expressed on 
the platelet membrane. Briefly, ADP and 5-HT are released from platelet dense 
granules and bind their specific receptors. Activation of the 5-HT2A receptor by 
5-HT and the P2Y1 receptor by ADP (both coupled to a Gq protein) induces an 
increase in intracellular Ca2+ levels, whereas activation of P2Y12 (couple to Gi 
protein) by ADP inhibits adenylate cyclase, blocking cyclic adenosine 
monophosphate (cAMP) production, a potent endogenous platelet inhibitor, and 
activates PI3kinase signallling leading to the integrins activation. TxA2 is 
synthesized in activated platelets starting from arachidonic acid (AA) by 
cyclooxygenase (COX). Once formed, TxA2 diffuses across the platelet 
membrane and activates other platelets through the interaction with two surface 
membrane TxA2 receptors, TPα and TPβ, coupled to the proteins Gq and G12 or 
G13, which activate phospholipase C (PLC). This enzyme degrades membrane 
phospholipids, thus releasing secondary messengers inositol triphosphate (IP3) 
and diacylglycerol (DAG). DAG activates intracellular protein kinase C (PKC), 
which causes protein phosphorylation, whereas IP3 increases cytosolic Ca
2+ 
levels from the endoplasmic reticulum. In addition platelets provide a catalytic 
surface necessary for local production of thrombin thus enhancing platelet 
activation. Indeed, at the site of injury prothrombin is proteolytically cleaved to 
form thrombin, a serine protease that converts soluble fibrinogen into insoluble 
strands of  fibrin. Subsequently, thrombin mediates cleavage of the N-terminal 
extradomain of protease-activated receptors (PAR)-1 and (PAR)-4, that 
increases intracellular calcium (Ca2+). The generation of thrombin is contingent 
upon the expression of tissue factor (TF) on the surface of fibroblasts, smooth 
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muscle cells, endothelial cells and leukocytes. Thrombin is among the most 
potent stimulators of platelets. 
 
Figure 1.3. Picture modified from [83] The antiadhesive phenotype of endothelial cells 
is maintained through four intrinsic pathways: ecto-ADPase, prostaglandin I2 (PGI2), 
nitric oxide (NO) and the thrombomodulin (TM)-activated protein C (APC) pathways. 
 
 
 
 
 
 Platelet Aggregation 
Aggregation is the amplification step that involves accumulation of platelets into 
the hemostatic thrombus through release of soluble agonists that enhance 
recruitment of further platelets. The stimulation of Gq and Gi signaling pathways 
leads to activation of the glycoprotein complex GPIIb/IIIa. Activated GPIIb/IIIa 
binds multiple ligands, including vWF [84] [85], fibrinogen [86], fibrin and 
fibronectin [87], able to form stable platelet aggregates [88]. The primary 
hemostatic plug is consolidated by fibrin generation at the site of injury. Platelet 
activation is under tight negative control to limit and contain thrombus formation 
within the boundaries of the lesion in the vessel wall. 
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1.2.3 The platelet P2Y12 receptor for adenosine 
diphosphate  
 ADP signalling in platelets 
Adenosine diphosphate (ADP), the first known low molecular weight platelet 
aggregating agent, plays an important role in platelet function despite being a 
weak platelet agonist. As such, it only induces platelet shape change and 
reversible aggregation in humans. Platelet secretion and secondary aggregation 
observed after stimulation with ADP of normal, human citrated platelet-rich 
plasma are due to the aggregation-dependent formation of TxA2. ADP is 
released in high concentration from platelet dense granules where it is stored 
and amplifies platelet responses induced by other agonists [89, 90] and 
stabilizes platelet aggregate [91, 92]. As previously described, ADP interacts 
with two different G protein coupled P2 receptors on the platelet surface: P2Y1 
and P2Y12.The signal transduction involves a transient rise in free cytoplasmic 
calcium trough the Gq-linked P2Y1 receptor, and the inhibition of adenylyl 
cyclase, mediated by the Gi-linked P2Y12 receptor [93]. The activation of P2Y1 
receptor by ADP mediates platelet shape change and initiates platelet 
aggregation, while P2Y12 amplifies platelet aggregation response[94]. 
Concomitant activation of both G protein-coupled receptors is essential to elicit 
normal platelet aggregation [93, 95] (Figure 3). 
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Figure 1.4. Figure modified from [96]. Role of P2Y12 in platelet aggregation. ADP 
interacts with P2Y12, a seven-transmembrane receptor that is coupled to Gi protein. 
This bond induces platelet aggregation and amplifies the aggregation response that is 
induced by other agonists or by ADP itself, by interacting with its other platelet 
receptor, P2Y1. P2Y12 stabilizes platelet aggregates and amplifies the secretion of 
platelet dense granules stimulated by secretion-inducing agonists (coupled to Gq). 
P2Y12 stimulation inhibits adenylyl cyclase (AC) through Gi, this function does not 
appear to be directly related to P2Y12 -mediated platelet activation. However, it could 
have important implications in vivo, where platelets are exposed to the inhibitory 
prostaglandin PGI2 (prostacyclin), which inhibits platelet aggregation by increasing 
platelet cyclic adenosine monophosphate (cAMP) through activation of AC mediated by 
Gs: inhibition of AC by P2Y12 counteracts the inhibitory effect of prostacyclin, thereby 
favoring the formation of platelet aggregates in vivo. 
 
 
 Platelet P2Y12 receptor 
The P2 receptors, which interact with purine and pyrimidine nucleotides, are 
divided into two groups: G protein-linked or metabotropic, termed P2Y, and 
ligand-gated ion channels or ionotropic, termed P2X [97]. The P2Y receptors 
are seven-membrane-spanning proteins with a molecular mass of 41 to 53 kD 
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after glycolysation [97]. The carboxyl terminal domain is on the cytoplasmatic 
side, whereas the amino terminal domain is exposed to extracellular 
environment. The mechanisms of signal transduction are shared by most 
seven-membrane-spanning receptors, and include activation of phospholipase 
C and regulation of adenylyl cyclase activity. The Gq coupled receptor P2Y1 
leads to activation of β-isoforms of phospholipase C (PLC) and triggers the 
mobilization of Ca2+ into the cytoplasm. The Gi coupled receptor P2Y12 leads to 
inhibition of adenyl cyclase (AC) with a decrease of intraplatelet cAMP. Co-
interaction of P2Y1 and P2Y12 is necessary for normal ADP-induced platelet 
aggregation, in fact separate inhibition of either of them with selective 
antagonists results in a dramatic decrease in aggregation [95, 98, 99]. The 
stimulation of the ADP receptors, predominately the P2Y12 receptor, assists to 
activation of integrin GP IIb/IIIa (fibrinogen receptor)[100, 101]. P2Y12 is 
important for both normal hemostasis and pathological thrombosis, this explains 
why P2Y12 receptor is one of the main target for antiplatelet drug. 
 
1.2.4 Platelet and inflammation 
In addition to their well characterized and established role in hemostasis and 
thrombosis, platelets have also inflammatory functions and influence innate and 
adaptive immune responses [102-104]. Basically, platelet increase endothelial 
permeability, leading to extravascular fluid accumulation, and when 
pathologically in disease.[105-107] 
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Figure 1.5: modified from [108] Direct and indirect platelet-leukocyte interactions: 
platelet and leukocyte surface receptors and the most important platelet α-granule 
derived cytokines that modulate leukocyte responses are depicted 
 
Platelet activation triggers exocytosis of platelet granules, which comprise a 
plethora of immune-modulatory factors[109] (Figure 1.5). Platelets express toll-
like receptors, which initiate the innate immune response; interact with activated 
endothelium, undergo chemotaxis, “prime” leukocytes for efficient tissue 
recruitment, and activate other inflammatory cells. [102-104]. 
Platelet dense granules content, including ADP and ATP, are important for 
activation and recruitment of further platelets. Platelet α-granules contain 
platelet factor 4 (PF4, CXCL4), macrophage inflammatory protein 1 (MIP-1, 
CCL3), regulated on activation, normal T cell expressed and secreted 
(RANTES, CCL5), neutrophil activating protein 2 (NAP-2, CXCL7), interleukin 8 
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(IL-8) and IL-1, CD40 ligand (CD40L) and P-selectin (CD62P), which are 
involved in recruitment and/or activation of leukocytes. [110-112]  
In particular, CD62P will bind to P-selectin glycoprotein ligand-1 on leukocytes 
and create platelet-leukocyte aggregates and trigger leukocyte activation. CD40 
interaction with CD40L on the platelet surface or soluble CD40L is an important 
mediator of platelet-induced adaptive immune responses. CD40 is expressed 
on mature B-cells, some T-helper (Th) cells and cytotoxic T-lymphocytes as well 
as platelets. Via CD40L platelets can directly induce B-cell antibody production 
and support Th1-cell-mediated germinal centre formation. [108] 
Recently, microRNAs, small non-coding RNA molecules such as miRNA-223, -
126, -21, -24, and -197, were found in platelets, secreted in exosomes and/or 
microvesicles upon platelet activation and once taken up by cells, can further 
trigger inflammatory processes and increase atherosclerosis and angiogenesis 
[113, 114].   
As result of leukocytes and EC activation, at the site of inflammation release of 
pro-inflammatory cytokines and adhesion receptors expression increase that 
further amplify the inflammatory process.[115] 
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Figure 1.6:  modified by [115] Illustration of the role of platelets in amplification of 
inflammation via interactions with leukocytes and endothelial cells and the release of 
cytokines from all cells involved. Platelets store pro-inflammatory cytokines that are 
released when platelets are activated. In addition activated platelets translocate 
adhesion receptors e.g. CD62P (P-selectin) and CD40L from their alpha granules to 
the plasma membrane. CD62P will bind to P-selectin glycoprotein ligand-1 on 
leukocytes and create platelet-leukocyte aggregates and trigger leukocyte activation. 
CD40L will bind to CD40 on a number of cells including endothelial cells (EC) and 
trigger their activation.  
 
 The platelet P2Y12 receptor in inflammation 
Several studies indicated that inflammatory disease conditions are associated 
with the extracellular release of nucleotides and highlighted fundamental roles 
for P2Y receptors during inflammatory and infectious diseases. The two P2Y 
receptor expressed on platelets have been shown to potentially play a role in 
inflammation. The platelet P2Y1 receptor contributes to P-selectin exposure, 
platelet-leukocyte aggregates formation and tissue factor exposure when 
platelets are stimulated with ADP, collagen or low concentrations of thrombin 
receptor agonist peptides [116, 117]. 
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 Some studies [118, 119] have documented decreased exposure of P-selectin, 
diminished formation of platelet-leukocyte aggregates, and less subsequent 
tissue factor exposure also in patients on treatment with thienopyridines, 
inhibitors of P2Y12 receptor such as ticlopidine and clopidogrel, demonstrating a 
potential role of the platelet P2Y12receptor in inflammation in vivo.  
In addition, it has been reported that the inhibition of CD40L exposure and 
release [120]  and the reduction of circulating levels of C-reactive protein in 
response to P2Y12 antagonists [121-123], supporting the role of P2Y12 in 
inflammatory processes. Clopidogrel withdrawal was associated with an 
increase in platelet and inflammatory biomarkers in diabetic patients[124] 
The  critical role of platelets in vascular inflammation and its inhibition by P2Y12 
antagonists has been demonstrated also in vitro both in humans and 
experimental animals. Indeed in a murine model of abdominal aortic aneurism, 
treatment with clopidogrel significantly suppressed aneurysm formation, 
inflammatory cytokine expression, infiltration of macrophages and production of 
matrix metalloproteinases[125]. Inhibition of P2Y12 receptors in vitro by 
clopidogrel’s active metabolite reduced P-selectin expression, platelet-
polymorphonuclear leukocytes adhesion and production of reactive oxygen 
species by polymorphonuclear leukocytes  [126].  
However, the inflammation-reducing effects of blocking P2Y12 have not been a 
persistent finding in all trials and the results of different studies in this field are 
sometimes contradictory [127-131].  
Another inhibitor of P2Y12 receptor, the active metabolite of prasugrel yielded in 
vitro a concentration-dependent inhibition of platelet aggregation, soluble 
CD40L release, and platelet-leukocyte aggregates formation in healthy 
volunteers [132]. The latter finding was confirmed by others [133] in human 
blood samples and extended to the inhibition of agonist-stimulated platelet-
monocyte adhesion in blood samples from mice [134].  
Prasugrel reduced tumour necrosis factor (TNF)-alpha synthesis and increased 
nitric oxide (NO) metabolites in endotoxin-treated mice in vivo [134]. On the 
other hand, the anti-inflammatory actions of the active metabolite of prasugrel 
was likely derived from direct targeting of neutrophils isolated from human blood 
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and was P2Y12 receptor independent [135]. In a randomized, placebo 
controlled, cross-over study it was recently shown that treatment with the 
thienopyridine P2Y12 antagonist prasugrel of patients with allergic asthma for 15 
days tended to reduce bronchial hyper-reactivity to mannitol. [136] This effect of 
prasugrel likely reflects a reduction in airway inflammation, because the 
mannitol test, like other forms of indirect airway challenge, more closely reflects 
active airway inflammation than the direct challenges, such as the metacholine 
test[137] The greater specificity of the mannitol test for detecting changes in 
airway hyper-responsiveness in asthma patients is likely explained by the fact 
that it mimics the normal pathophysiology of bronchial asthma, causing the 
release of various mediators of bronchoconstriction[138] Although the results of 
this study cannot clarify whether the effect of prasugrel was mediated by its 
interaction with P2Y12 on platelets or other cells, the former hypothesis is 
supported by the results of experimental studies that demonstrated the 
important role of platelet P2Y12 in the recruitment of inflammatory cells in lungs 
of sensitized mice challenged with cysteinyl leukotrienes [14, 139] 
 
 
1.3 CYSTENYL LEUKOTRIENES AND PLATELET 
IN INFLAMMATION 
Allergic bronchial asthma is a chronic inflammatory disease that impairs the 
quality of life and is associated with significant mortality rate. In 1981, it was 
shown that platelets are activated during antigen-induced bronchocostriction 
[140] As mentioned before Cysteinyl-Leukotrienes interact with G protein-
coupled receptors and play a role in allergic asthma. Platelets adhere to 
leukocytes and amplify the production of Cysteinyl-LTs [141], express CysLT1R 
and CysLT2R and, when exposed to LTD4 or LTE4, release RANTES, a 
powerful eosinophil chemoattractant [27]. More recently, it was shown that 
platelets accumulate in lungs of asthmatic patients, are required for airway wall 
remodelling and recruitment of inflammatory cells in murine allergic lung 
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inflammation [142, 143] and migrate into the lungs of ovalbumin sensitized and -
challenged mice by an IgE dependent mechanism [144]. Recently, it was shown 
that LTE4 enhances inflammatory cell recruitment in lungs of sensitized mice, 
which is abrogated by platelet depletion, by treatment with the anti-P2Y12 
thienopyridine drug clopidogrel[145], and in mice lacking P2Y12, but not in mice 
lacking CysLT1R and CysLT2R [14] Moreover, intranasal administration of LTC4 
in sensitized mice before ovalbumin challenges potentiated the recruitment of 
eosinophils in the bronchoalveolar lavage, which was dependent on CysLT2R, 
but also on P2Y12 and platelets [139]. The mechanism by which the platelet 
P2Y12 contributes to the effects of cysteinyl- leukotrienes is uncertain. Because 
LTE4 shows negligible activity at CysLT1R and CysLT2R, its biological effects 
are likely mediated by a third, elusive receptor, which was tentatively identified 
with P2Y12, based on computer modelling and the demonstration that LTE4 
signals through P2Y12 in transfected cells [73] However, more recently GPR99 
was identified as the elusive receptor for LTE4[36]. Moreover, studies that 
demonstrated the important role played by platelet P2Y12 in LTE4 or LTC4-
induced enhanced recruitment of inflammatory cells in the lungs of sensitized 
mice failed to show that the CysLT interact directly with the platelet P2Y12, 
which might therefore play an indirect, albeit important role in the process [14, 
139, 141] CysLTs induced concentration dependent calcium mobilisation in 
cells overexpressing CysLT1R and CysLT2R but failed to induce any calcium 
response in cells expressing P2Y12. Similarly, specific response to 2-MeS-ADP, 
but not to cysLTs was also observed in cells expressing P2Y12 when 
intracellular cAMP and beta-arrestin signalling. [146] Also in human platelets 
LTE4 cannot affect the externalization of P-selectin or the production of cAMP. 
[146]. So far, the role of cystenyl leukotrienes in platelet aggregation is not well 
described. In 1986 Metha et al.[147] indicate that leukotrienes alone had no 
direct effect on platelet aggregation, but potentiated the effects of subthreshold 
concentrations of epinephrine and thrombin, indendenty by prence of Calcium. 
Cystenyl leukotrienes potentiate epinephrine-induced platelet aggregation by 
modulating TXA2 synthetase activity. Independently of whether it plays a direct 
or an indirect role in the inflammatory process, these data clearly suggest that 
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the platelet P2Y12 represents an ideal pharmacological target for the treatment 
of allergic asthma. The demonstration that P2Y12 variants are associated with 
lung function in a large family-based asthma cohort and that house dust mite 
modulates these associations through gene-by-environment effects provided 
the first human evidence supporting a role for P2Y12 in this disorder [148].The 
role of platelets in inflammatory processes, in particular, has gained particular 
attention in the last three decades. Among the many platelet receptors and 
molecules that are involved in inflammation, the platelet P2Y12 receptor for ADP 
has recently been implicated in the pathogenesis of allergic asthma, through its 
direct or indirect interactions with cysteinyl-leukotrienes. Both an observational, 
epidemiologic study and, more recently, a small, proof-of-concept randomized 
clinical trial supported the hypothesis that P2Y12 may represent an important 
pharmacological target for the treatment of patients with allergic bronchial 
asthma. 
  
26 
 
 
 
 
 
 
 
 
 
 
2. AIM OF THE STUDY 
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Aim of this study was to test whether cystenyl leukotrienes elicit platelet 
functional responses, by interacting with the platelet P2Y12, receptor for ADP. 
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3. MATERIALS AND METHODS 
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3.1 REAGENTS 
Epinephrine and ADP were supplied by Sigma Aldrich (Milano, IT). Cangrelor 
(Can) was from The Medicines Company, USA. LTC4, LTD4 and LTE4 purity ≥
97%), were supplied by Cayman Chemical Company, Ann Arbor, MI, USA. 
The fixative solvent PamFIX were supplied by Platelet Solution (Nottingham, 
UK).  
Hirudin ReVasc powder was supplied by Boehringer Ingelheim RCV GmbH 
(Vienna, Austria)  Each vial contains 15 mg desirudin corresponding to 
approximately 270,000 antithrombin units (ATU) or 18,000 ATU per mg of 
desirudin with reference to the WHO Second International Standard for alpha-
thrombin. 
Antibody for P-selectin is a PE Mouse Anti-Human CD62P, clone  AK-4. It’s 
matching isotype control is a Mouse IgG1, κ, as indicated in data sheet. 
Antibody used to identify platelet is an APC-Mouse. Anti-Human CD42b, 
clone  HIP1.  
All antibodies were supplied by Bekton Dickinson Italia S.p.A.  
Cell culture supplies (media, serum, supplements and antibiotics) and TRIzol 
were from Gibco Life Technologies (LifeTechnologies Italia, Monza, MB, Italy). 
Laboratory disposable products (Petri, multi-well plates, etc.) were from 
Euroclone (Pero,MI, Italy). 
Montelukast was kindly provided by Merck (Merck & Co., West Point, PA). 
AP100984-2A was a kind gift from Dr. J. Evans, Amira Pharmaceuticals (San 
Diego, CA). 
 
3.2 HEALTHY SUBJECTS 
Twenty-four apparently healthy subjects were studied, who were recruited 
among the laboratory personnel and medical students of our institution. All 
subjects abstained from any drug known to affect platelet function for at least 
10 days before blood sampling. 
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3.3 BLOOD SAMPLING 
Patients had to refrain from smoking for at least 2h before blood sampling; a 
light breakfast was allowed in the morning of the study. Blood samples were 
collected from an antecubital vein, using a 21-gauge butterfly needle and a 
tourniquet, released soon after needle insertion. The first 3 mL of blood were 
collected into K-EDTA and analyzed by coulter hematology analyzer (Beckman 
Coulter, Milano, IT); the following blood was collected into plastic PP tubes 
containing trisodium citrate (109 mM, 1:9, v/v) or Hirudin ReVasc (5 mg/mL;  
18,000 ATU per mg of desirudin)  gently mixed, allowed “ to rest” at room 
temperature for 15 min, and used for platelet aggregation studies. 
For P-selectin experiments (flow cytometry) blood samples were collected in 
commercial tubes containing sodium citrate (109 mM, 1:9, v/v; Sarsted) and a 
cocktail, simultaneously added, containing Na2EDTA (50mM), N-ethylmaleimide 
(60mM), and aprotinin (2000 KIU/mL) to inhibit the activity of protease. [149] 
 
3.4 PLATELET AGGREGATION 
Platelet aggregation was measured by light transmission aggregometry (model 
PAP-8E, Biodata, Horsham, PA, USA) in platelet rich plasma (PRP), obtained 
by centrifugation of citrate or hirudin whole blood at 200 x g for 10 min at room 
temperature [150]. Autologous platelet-poor plasma (PPP) was obtained by 
centrifugation of blood samples at 1.400 x g for 15 min at room temperature. 
Autologous PPP was used to set the instrument’s 100% light transmission, 
while unstimulated PRP was used to set 0% light transmission. The individual 
platelet count of PRP samples was not adjusted to a pre-determined range, 
because this procedure may induce artefacts [151]. We tested the effect of 
leukotrienes on platelet aggregation in two different experimental situations: in 
citrate-PRP (low concentration of ionized calcium) and in hirudin-PRP 
(physiological concentration of ionized calcium). All aggregation tests were 
performed within 3 hours after blood collection.  
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Briefly, PRP was placed into a test tube containing a stir bar, test compound 
(LTC4 0.8 µM , LTD4 1 µM, or LTE4 1.1 µM) or vehicle (ethanol 0.25%) was 
added without stirring and incubated at 37 °C for three different times: 0, 3, and 
6 minutes, then the aggregation was induced by ADP or Epinephrine at two 
different concentrations (0.1 µM and 1 µM) and recorded for 6 minutes. The 
maximal aggregation response, expressed as percent increase in light 
transmission, was measured. 
 
3.5 MEASUREMENT OF PLATELET cAMP 
Platelet cAMP was measured by a radioisotopic assay, using a commercially 
available kit (Cyclic AMP [3H] assay system; Amersham International, UK). 
Duplicate samples of 1 mL citrated PRP were incubated at 37°C for 2 minutes 
with a mixture containing theophylline (1 mM), PGE1 (2 μM), and Tyrode’s 
buffer or ADP (0.1 μM) in presence and absence of LTC4 (0.5 µM) or LTE4 (0.5 
µM). A set of these experiments with LTC4  was carried out in presence and 
absence of cangrelor (1 µM). After incubation, 1 mL of 5% trichloroacetic acid 
was added, and the samples were snap-frozen in dry ice and methanol, thawed 
at ambient temperature, and then shaken at 4°C for 45 minutes. After 
centrifugation at 4°C for 30 minutes, the supernatant was extracted 3 times with 
5 mL of water-saturated ether, dried under a stream of nitrogen at 60°C, and 
stored at −20°C. Before assay, the samples were reconstituted with 0.05 mol/L 
Tris buffer containing 4 mmol/L EDTA. [152] 
3.6 FLOW CYTOMETRY 
3.6.1 Stimulation of blood samples 
Blood samples were diluted 1:2 with sterile saline solution [153, 154] and then 
stimulated with LTC4 (0.8 µM) or LTD4 (1 µM) or LTE4 (1.1 µM) or vehicle 
(Ethanol, compounds used for dissolving leukotrienes) in presence or not of 
cangrelor 1µM, at room temperature, without stirring, for 25 minutes. Then 
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saline, ADP 0,1 µM or ADP 1 µM was added, the samples were gently mixed 
and left for 5 minutes at room temperature without stirring.  
The reaction was stopped by addition of fixative (PAMFix) at a ratio of 2 
volumes of PAMFix to 1 volume of the sample. Fixed samples were stored at 
4°C and then analysed between 24 hours and 9 days [153]  
3.6.2 Labelling and analyses at flow cytometer 
Fixed samples were labelled with a cocktail of the following antibodies: anti-
human APC labelled CD42b (used to identify platelets), - PE labelled anti-
CD62P (used to identify P-selectin) or isotype-matched control antibodies in a 
ratio of 9 volumes of stimulated blood and 1 volume of each antibody. After one 
hour of incubation in dark, the samples were analyse by using FACSverseTM BD 
FACS verse 6 color flow cytometry. 
Calibration beads automate the characterization of cytometer fluorescence 
detectors and the entire optical configuration by creating baselines with 
performance values, which have to be targeted prior to each measurement to 
ensure standardized performance. 
BD FACSuite™ software controls the connection between the flow cytometer 
and instruments being the platform to perform calibration and acquisition.  
All samples were acquired with a slow flow rate, and for each samples 5000 
events were recorded. 
3.6.3 Titration curve 
Immediately after the puncture the blood was stimulated at room temperature, 
without stirring for 5 minutes with TRAP 10 µM. The same amount of blood was 
incubated with increasing amount of antibody CD42b-APC and CD62P-PE:0.25; 
0.5; 1, 2 and 5 µL of each antibody with 20 µL of blood. 
The sample were acquired with same instrument and program of sample 
described above. 
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3.6.4  Gating strategy 
We evaluated P-selectin expression in a whole blood sample, but we were 
interested only in platelet, then we acquired with threshold in APC labelled to 
CD42b (identifier of the platelets). The cloud of platelet appeared clear in a dot-
plot graph with FSC parameter on x axis and SSC parameter on y axis, in a 
logarithmic scale. In this graph we traced the cloud named platelet.  (Fig 3.1) 
By using a dot plot CD42b-APC vs CD62P-PE, we plotted cells gated in 
“platelet” and we defined the positive cells basing on isotype control. (Fig 3.1) 
We fixed the isotype control at a maximum of 4% of positive to CD62P cells.  
The analytic parameter used to evaluate the level of P-selectin expression was 
always the % of cells positive to the antibody CD62P.  
 
 
Figure 3.1: Measurement of P-selectin by flowcytometer: isotype control.  
 
Figure 3.2: Measurement of P-selectin by flowcytometer: expression of p-selectin after 
stimulation with increasing concentration of ADP  
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3.7 MASS SPECTROMETRY  
 
Mass spectrometry was performed using an ABSciex 3200 QTrap mass 
spectrometer equipped with an ESI ion source and combined with HPLC 
(Ultimate 3000 Dionex) . Data acquisition and elaboration were carried out by 
Analyst software Ver. 1.6 (ABSciex).  
Operating conditions for the ESI source, used in the negative ionization mode, 
were optimized by adding standard stock solutions containing LTC4, LTD4, and 
LTE4 in ethanol 10 ng/µL) to the HPLC flow. Mobile phase consisted of 
acetonitrile–water–formic acid (20:80:0.1, v/v/v) and the flow rate was 0.3 
mL/min. The injection volume was 10  μL for each LT . The parameter settings 
were the followings: source temperature of 600°C, spray voltage of 4000 V, 
curtain gas of 25 psi, ion source gas 1 of 55 psi, ion source gas 2 of 70 psi, 
collision gas of 6 arbitrary units and dwell time of 65 ms per ion.  [155] 
The resulting mass spectra were acquired in the full-scan mode (scan range: 
m/z 150 – m/z 650) and the product ions (624 m/z for LTC4 , 495 for LTD4, 438 
for LTE4) were extracted and analysed. 
 
 
3.8 RESPONSES OF HUMAN UMBILICAL VEIN ENDOTHELIAL 
CELLS TO CysLTs 
3.8.1 Preparation of human umbilical vein endothelial cells 
ECs were isolated from human umbilical cord veins (HUVECs) obtained after 
informed consent at the G. Salvini Hospital (Garbagnate Milanese, MI, Italy) and 
at the Fatebenefratelli Hospital (Erba, CO, Italy). The veins were cannulated 
and perfused with sterile physiological solution (0.9% NaCl); after incubation 
with Collagenase A (0.015–0.035% in Dulbecco’s Phosphate Buffered Saline – 
D-PBS) at 37◦C for 15 min, ECs were centrifuged (15 min, 280 g), resuspended 
in M199 supplemented with 20%fetal calf serum (FCS), 0.1 mg/ml heparin, 0.1 
mg/mL ECGF, 1% penicillin/streptomycin/fungizone solution, and then cultured 
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in gelatin-precoated flasks (25 cm2). After reaching confluence, cells were 
treated with trypsin and seeded into the appropriate Petri dishes, trans well 
filters or glass covers lips and allowed to expand to the desired confluence for 
subsequent use. Cells were used up to the third passage. [[156]] 
 
 
3.8.2 Real-time impedance analysis of HUVECs response to cysteinyl-LTs 
HUVECs were seeded onto E-Plate L8 (ACEA Bioscience, SanDiego, CA) 
precoated with gelatin 0.1% and used at 80% confluence. CysLT2cpd or vehicle 
were added 15 min before CysLTs (LTC4 or LTD4 or LTE4 0.1µM) and changes 
in electrical impedance were measured by i-Celligence Real Time Cell Analyzer 
(ACEA Bioscience) at 37◦C and 5% CO2 for 15 minutes. [[156]] 
 
3.8.3 Determination of cytosolic Ca2+ levels 
HUVECs cells were seeded onto 12-mm diameter glass covers lips and used 
when 80–90% confluence was reached. Cells were incubated for 60 min at 
37°C in the dark with 2  µmol/L  fura2/AM in saline solution (NaCl 145 mmol/L, 
KCl 5 mmol/L, MgCl21 mmol/L, CaCl21.8 mmol/L, HEPES 10 mmol/L, glucose 
10 mmol/L; pH 7.4) plus 0.03% pluronic F-127. After loading, the cells were 
washed  twice with a saline solution. The covers lips were transferred to a 
spectrofluorimeter (Perkin Elmer LS50) cuvette and fluorescence was 
monitored at 37◦C (505 nm emission, 340 and380 nm excitation). In order to 
evaluate the concentration of cytosolic-free Ca2+ ion ([Ca2+]i) from fluorescence 
recording, calibration was performed as follows: Fmax(maximal fluorescence of 
the system) was obtained by adding 2  µmol/L ionomycin and 100  µmol/L 
digitonin, Fmin was obtained by adding 5 mmol/L EGTA and 60 mmol/L Tris 
base. [Ca2+]i  was calculated as described by Grynkiewicz [157] with a Kd= 224 
nmol/L. Values were expressed as fold increase over basal. [156] 
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3.9 STATISTICAL ANALYSIS 
All statistical analyses were performed using GraphPad Prism Ver.5 (GraphPad 
Software Inc, CA, USA). Normal distribution was evaluated by D'Agostino-
Pearson test. Parametric or non-parametric tests were used as appropriated. 
For comparison among multiple groups one-way ANOVA or Friedman test was 
used followed by Bonferroni or Dunn’ post hoc test, respectively. 
Differences were considered statistically significant with p-value<0.05.  
Results were expressed as mean and standard deviations. 
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4. RESULTS 
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4.1 CHARACTERIZATION OF CYSTENYL LEUKOTRIENES  
4.1.1 Identification of leukotrienes  by mass spectrometry 
The mass spectra acquisition was performed in negative ESI, because all 
tested compounds have a carboxyl group which confers a negative charge. 
Negative electrospray full-scan mass spectra of CysLTs indicated the presence 
of the proper deprotonated molecules [M -H]- as the predominant ion for each 
compound, confirming the presence of the stable  CysLTs  in the solutions used 
in all experiments reported in this work . The product ion mass spectra of the 
analytes [M-H]- are reported in table 4.1 and Figure 4.1. 
 
Compound 
Molecular 
Formula 
Molecular 
Weight 
Monomer [M-H]-
m/z 
LTC4 C30H47N3O9S 625 624 
LTD4 C25H40N2O6S 496 495 
LTE4 C23H37NO5S 439 438 
    
Table 4.1 Pseudomolecular and adduct ions in the ESI negative mass spectra of 
CysLTs 
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LTC4 
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Figure 4.1  Full scan spectra of Vehicle (ethanol),  LTC4, LTD4, and LTE4 
 
 
LTE4 
LTD4 
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4.1.2 Effects of CysLTs on cytosolic free Ca2+ levels 
All tested CysLTs induced an increase in Ca2+ levels in HUVEC: the highest 
increase was observed with LTC4, the lowest with LTE4. AP100984-2A (1 µM), a 
selective inhibitor of CysLT2R, inhibited the increase in [Ca
2+] activated by LTC4 
(Fig 4.2) 
 
Figure 4.2: Effects of LTC4, LTD4, and LTE4 at the indicated concentrations on [Ca
2+]I 
transients in HUVEC. The effects of LTC4 were measured also in the presence of the 
CYsLT2 receptor antagonist (AP100984-2A). 
 
4.1.3 Effects of CysLTs on impedance of HUVEC cells 
LTC4 decreased the impedance of HUVEC (Fig4.3); its effect was inhibited by  
AP100984-2A (1µM), but not by Montelukast (1 µM), a selective inhibitor of 
CysLT1R. (FIG 4.3).  Similar results, albeit  of lower intensity, were observed 
with LTD4 (Fig 4.4) and LTE4 (Fig4.5), confirming previously published results 
by Capra et al. [156]. 
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 Figure 4.3: Effects of LTC4 on impedance of HUVEC, in the presence and absence of 
AP100984-2A (1µM), a selective inhibitor of CysLT2R or Montelukast (1 µM), a 
selective inhibitor of CysLT1R 
 
Figure 4.4: Effects of LTD4 on impedance of HUVEC, in the presence and absence of 
AP100984-2A (1µM), a selective inhibitor of CysLT2R or Montelukast (1 µM), a 
selective inhibitor of CysLT1R 
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Figure 4.5: Effects of LTE4 on impedance of HUVEC, in the presence and absence of 
AP100984-2A (1µM), a selective inhibitor of CysLT2R or Montelukast (1 µM), a 
selective inhibitor of CysLT1.  
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4.2 Platelet aggregation 
Incubation of LTC4 (0.8 µM), LTD4 (1 µM), and LTE4 (1.1 µM) with normal 
human PRP for up to 6 min did not cause platelet aggregation, independently of 
the type of anticoagulant used to collect blood samples (citrate or hirudin)  
(Table 4.2) 
 
 Max aggregation (%) 
  CITRATE     HIRUDIN     
  0 min 3 min 6 min 0 min 3 min 6 min 
Vehicle 
3,3 2,0 1,6 1,6 0,8 1,2 
(1,8) (1,7) (2,1) (0,9) (0,4) (0,4) 
LTC4 (0.8 µM) 
2,8 2,3 1,6 1,2 1,2 1,2 
(1,3) (1,5) (1,3) (0,4) (0,4) (0,8) 
Vehicle 
2,0 1,8 1,7 1,8 0,8 1,0 
(0,9) (1,2) (1,4) (0,8) (0,4) (0,6) 
LTD4 (1 µM) 
2,0 1,2 1,5 1,5 1,0 0,8 
(0,9) (0,8) (0,5) (1,0) (0,6) (0,8) 
Vehicle 
2,7 2,3 2,1 1,5 0,6 0,8 
(1,6) (1,7) (2,3) (0,7) (0,5) (0,6) 
LTE4 (1.1 µM) 
3,1 2,5 2,4 1,8 0,7 0,9 
(2,1) (1,6) (2,4) (1,9) (0,7) (0,7) 
 
Table 4.2: Platelet aggregation in human PRP, measured as % increase of light 
transmission. Date are reported as means and standard deviations: n=6 for LTC4 and 
LTD4, and n=11 for  LTE4. 
 
When added to citrate or hirudin PRP in combination with different 
concentrations of the platelet agonists ADP or epinephrine (0.1 – 1.0 µM) LTC4 
(Tab. 4.3 and Tab 4.6), LTD4 (Tab. 4.4 and Tab 4.6), and LTE4 (Tab. 4.5 and 
Tab 4.7 ) did not enhance agonist-induced platelet aggregation, independently 
of the length of incubation of CysLTs with PRP. 
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Table 4.3: Plateletaggregation in citrate-PRP induced by ADP or Epinephrine in 
presence/absence of LTC4, which had been incubated with PRP for 0 min (added 
together with the platelet agonist), 3 or 6 min before the addition of the platelet agonist.  
Data are reported as means and standard deviations ( n=3)  
 
 
 
 % of aggregation 
 Agonist 0.1 µM Agonist 1 µM 
 Vehicle LTC4 0,8µM Vehicle LTC4 0,8µM 
 0 min  incubation 
Vehicle 
3.7 
(2.1) 
3.0 
(1.7) 
3 
(1.7) 
2,7 
(1.2) 
Epinephrine 
8.0 
(4.4) 
7.0 
(4.6) 
73,7 
(8.0) 
71,7 
(4.7) 
ADP  
4.0 
(4.4) 
4.0 
(3.5) 
11,3 
(3.2) 
10,7 
(2.1) 
  
3 min incubation 
Vehicle  
2,3 
(2.3) 
2,7 
(2.1) 
1,7 
(1.2) 
2 
(1.0) 
Epinephrine  
5,7 
(4.0) 
5,3 
(2.5) 
66.3 
(8.5) 
71,0 
(14.4) 
ADP  
2,7 
(2.9) 
4,7 
(5.5) 
9.3 
(1.5) 
9,7 
(2.5) 
  6 min incubation 
Vehicle  
2,0 
(2.6) 
2,0 
(1.7) 
1 
(1.4) 
1 
(0.0) 
Epinephrine  
4,3 
(2.3) 
5,7 
(4.0) 
71,3 
(17.0) 
70 
(16.6) 
ADP  
3,0 
(4.4) 
3,0 
(2.6) 
8,7 
(2.9) 
8,3 
(3.2) 
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Table 4.4: Platelet aggregation in citrate-PRP induced by ADP or Epinephrine in 
presence/absence of LTD4, which had been incubated with PRP for 0 min (added 
together with the platelet agonist), 3 or 6 min before the addition of the platelet agonist.  
Data are reported as means and standard deviations ( n=3)  
 
 
 
 
 
 
 
 
 
 % of aggregation 
 Agonist 0.1 µM Agonist 1 µM 
 Vehicle LTD4 0,8µM Vehicle LTD4 0,8µM 
 0 min  incubation 
Vehicle 
2.0 
(1.0) 
2.0 
(1.0) 
2.0 
(1.0) 
2.0 
(1.0) 
Epinephrine 
15 
(20.1) 
18.0 
(23.5) 
30.3 
(23.5) 
26.7 
(27.1) 
ADP  
2.3 
(1.5) 
1.7 
(0.6) 
13.0 
(4.4) 
13.3 
(2.3) 
  
3 min incubation 
Vehicle  
1.3 
(1.5) 
1.0 
(1.0) 
2.3 
(0.6) 
1.3 
(0.6) 
Epinephrine  
14.7 
(21.1) 
18,3 
(25.7) 
26.0 
(25.0) 
25.7 
(34.1) 
ADP  
1.0 
(1.0) 
1,7 
(1.2) 
11.7 
(3.1) 
11.0 
(3.6) 
  6 min incubation 
Vehicle  
1.7 
(2.1) 
1.3 
(0.6) 
1.7 
(0.6) 
1.7 
(0.6) 
Epinephrine  
3.0 
(2.6) 
3.0 
(2.6) 
24.7 
(31.5) 
20.3 
(27.5) 
ADP  
1.7 
(1.2) 
2.0 
(0.0) 
12.3 
(2.5) 
11.7 
(2.5) 
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 % of aggregation   % of aggregation 
  Agonist 0.1 µM  Agonist 1 µM    Agonist 0.1 µM  Agonist 1 µM  
  Veh LTE4 1.1 µM  veh LTE4  1.1 µM   veh LTE4  1.1 µM veh LTE4  1.1 µM 
  0 min    0 min  
Veh 
4.0 
(1.0) 
5.0 
(2.2) 
1,7 
(0.6) 
2,3 
(1.2) 
Veh  
3.1 
(1.7) 
3.4 
(2.3) 
2.3 
(1.6) 
2,4 
(1.7) 
ADP  
4.3 
(1.5) 
4.0 
(1.0) 
9,3 
(6.1) 
8,7 
(6.7) EPI 
8.4 
(5.4) 
9.3 
(7.0) 
30.3 
(27.6) 
32.1 
(25.8) 
  3 min    3 min  
Veh 
3.3 
(0.6) 
3.3 
(0.6) 
1.3 
(1.5) 
1.7 
(0.6) 
Veh 
2.6 
(1.8) 
2.8 
(1.8) 
1.9 
(1.9) 
2,1 
(1.8) 
ADP  
3.7 
(2.1) 
3.3 
(2.1) 
7.0 
(6.1) 
8.3 
(5.1) EPI 
12,8 
(19.1) 
6,9 
(5.6) 
30,4 
(25.2) 
28,5 
(21.7) 
  6 min    6 min  
Veh 
2,7 
(2.5) 
3,3 
(1.5) 
1.0 
(1.0) 
1.0 
(1.0) 
Veh  
2,6 
(2.6) 
3.0 
(2.6) 
1,9 
(2.3) 
2 
(2.7) 
ADP  
3,3 
(1.5) 
3,7 
(2.1) 
7.0 
(5.3) 
12 
(13.9) EPI 
10,1 
(11.4) 
13,3 
(19.0) 
25,4 
(28.6) 
25,4 
(25.1) 
A      B 
Table 4.5: Platelet aggregation in citrate-PRP induced by ADP (Panel A,) or 
Epinephrine (Panel B;) in presence/absence of LTE4, which had been incubated with 
PRP for 0 min (added together with the platelet agonist), 3 or 6 min before the addition 
of the platelet agonist.  The results are reported as mean and standard deviation of 3 
experiments for aggregation induced by ADP, and as mean and standard deviation of 8 
experiments for aggregation induced by epinephrine 
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  % of aggregation   % of aggregation 
  Agonist 0.1 µM  Agonist 1 µM    Agonist 0.1 µM  Agonist 1 µM  
  Veh LTC4 0,8µM  Veh LTC4 0,8µM   Vehi  LTD4 1 µM  Vehi LTD4 1 µM 
  0 min    0 min  
Vehicle  
2.0 
(1.0) 
1,3 
(0.6) 
1.0 
(0.0) 
1.0 
(0.0) 
Vehicle  
2.0 
(1.0) 
2.0 
(1.0) 
1.7 
(0.6) 
1.0 
(1.0) 
EPI 
1.7 
(0.6) 
2.0 
(1.0) 
1.7 
(0.6) 
1.7 
(0.6) EPI 
1.7 
(1.2) 
1.3 
(0.6) 
2.3 
(1.5) 
1.3 
(0.6) 
ADP  
0.7 
(1.2) 
0.7 
(0.6) 
15.0 
(2.0) 
11.7 
(4.9) ADP  
0.3 
(0.6) 
0.7 
(0.6) 
19.0 
(7.2) 
17.0 
(1.7) 
  3 min    3 min  
Vehicle  
1.0 
(0.0) 
1.3 
(0.6) 
0.7 
(0.6) 
1 
(0.0) 
Vehicle  
0.7 
(0.6) 
1.3 
(0.6) 
1.0 
(0.0) 
0.7 
(0.6) 
EPI 
1.7 
(1.2) 
1.3 
(0.6) 
0.3 
(0.6) 
0.3 
(0.6) EPI 
0.7 
(0.6) 
0.3 
(0.6) 
1.0 
(0.0) 
0.7 
(0.6) 
ADP  
0.0 
(0.0) 
0,7 
(0.6) 
12.0 
(0.0) 
11.3 
(1.2) ADP  
0.3 
(0.6) 
0.0 
(0.0) 
15.0 
(4.6) 
14.0 
(3.5) 
  6 min    6 min  
Vehicle  
1.3 
(0.6) 
1.0 
(1.0) 
1.0 
(0.0) 
1.5 
(0.7) 
Vehicle  
1.0 
(1.0) 
1.0 
(1.0) 
1.0 
(0.0) 
0.7 
(0.0) 
EPI 
1.0 
(1.0) 
0.7 
(0.6) 
0.7 
(0.6) 
1.0 
(0.0) EPI 
0.7 
(1.2) 
1.0 
(1.0) 
1.0 
(0.0) 
1.0 
(0.0) 
ADP  
0.0 
(0.0) 
1.0 
(1.0) 
13.0 
(1.0) 
9.7 
(4.2) ADP  
1.0 
(1.0) 
0.0 
(0.0) 
16.3 
(5.0) 
14.3 
(1.2) 
A      B 
Table 4.6: Platelet aggregation in hirudin-PRP induced by ADP or Epinephrine in 
presence/absence of LTC4 (Panel A) or LTD4 (Panel B), which had been incubated with 
PRP for 0 min (added together with the platelet agonist), 3 or 6 min before the addition 
of the platelet agonist.   Data are reported as mean and standard deviation (n=3) 
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  Hirudine  (% of aggregation)   Hirudine  (% of aggregation) 
  Agonist 0.1 µM  Agonist 1 µM    Agonist 0.1 µM  Agonist 1 µM  
  Vehi  LTE4 1.1µM  Vehi  LTE4 1.1µM   Vehi  LTE4 1.1µM Vehi  LTE4 1.1µM 
  0 min    0 min  
Vehicle  
1.7 
(1.2) 
3.3 
(3.2) 
1.3 
(0.6) 
1.0 
(0.0) 
Vehicle  
1.6 
(0.8) 
2.1 
(2.2) 
1.4 
(0.5) 
1.1 
(0.4) 
ADP  
0.3 
(0.6) 
0.3 
(0.6) 
9.7 
(6.0) 
10.0 
(6.0) EPI 
1.3 
(1.0) 
2.0 
(1.1) 
1.3 
(1.2) 
1.6 
(1.1) 
  3 min    3 min  
Vehicle  
1.0 
(0.0) 
1.0 
(1.0) 
0.3 
(0.6) 
0.7 
(0.6) 
Vehicle  
0.7 
(0.5) 
0.7 
(0.8) 
0.4 
(0.5) 
0.6 
(0.5) 
ADP  
0.0 
(0.0) 
0.0 
(0.0) 
7.7 
(4.2) 
9.0 
(4.6) EPI 
0.8 
(0.7) 
1.0 
(0.8) 
0.9 
(0.4) 
0.8 
(0.5) 
  6 min    6 min  
Vehicle  
1.3 
(0.6) 
1.3 
(0.6) 
0.3 
(1.0) 
1.0 
0.6) 
Vehicle  
1.0 
(0.6) 
0.9 
(0.7) 
0.6 
(0.5) 
0.7 
(0.8) 
ADP  
0.3 
(0.6) 
0.0 
(0.0) 
10.0 
(6.2) 
7.3 
(5.2) EPI 
0.9 
(0.8) 
1.1 
(1.1) 
0.6 
(0.7) 
1.4 
(1.1) 
A      B  
Table 4.7:  Platelet aggregation in hirudin-PRP induced by ADP (Panel A) or 
Epinephrine (Panel B) in presence/absence of LTE4, which had been incubated with 
PRP for 0 min (added together with the platelet agonist), 3 or 6 min before the addition 
of the platelet agonist. The results are reported as mean and standard deviation of 3 
experiments for aggregation induced by ADP, and as mean and standard deviation of 8 
experiments for aggregation induced by epinephrine. 
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4.3 EFFECTS OF CYSTENYL LEUKOTRIENES ON THE  
INHIBITION BY ADP OF PGE1-INDUCED PLATELET 
PRODUCTION OF CYCLIC-AMP  
PGE1 (2µM) increased platelet cAMP levels in citrate PRP, which were partially 
decreased by treatment with ADP. CysLTs had no significant effect on cAMP 
accumulation, both in the presence and absence of ADP. (Fig 4.5) 
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Figure 4.5. Effects of ADP, LTE4 and LTC4 in various combinations on the increase in 
platelet cAMP induced by PGE1.  
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4.4 EFFECTS OF CYSTENYL LEUKOTRIENES ON P-SELECTIN 
EXPRESSION 
   
ADP caused an increase in platelet p-selectin expression in a dose-dependent 
manner [158, 159], which was inhibited by  cangrelor (1 µM) (FIG 4.6) 
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Figure 4.6: Expression of platelet P-selectin after stimulation of whole blood by ADP in 
the presence and absence of cangrelor. Values were normally distributed. p<0.0001 
(ANOVA for repeated measures). Internal contrasts (Bonferroni’s test): vehicle vs ADP 
0.1 µM p<0.01, vehicle vs ADP 1 µM p<0.0001. 
 
Incubation of LTC4 (0.8 µM), LTD4 (1 µM), or LTE4 (1.1 µM) with whole blood for 
30 min, in the presence/absence of cangrelor,  did not increase the expression 
of P-selectin on platelets. ANOVA: p>ns  (FIG 4.7). 
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Figure 4.7: Expression of P-selectin after treatment with  CysLTs: none of them 
increased the level of P-selectin expression (ANOVA p=ns), in presence or absence of 
cangrelor 
 
Incubation of whole blood with LTC4 (0.8 µM), LTD4 (1 µM), or LTE4 (1.1 µM) in 
combination with ADP 0.1 µM for 30 min did not significantly increase the 
expression of p-selectin on platelets, in the presence/absence of cangrelor  
(FIG 4.8). 
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Figure 4.8: Expression of P-selectin in whole blood after treatment with CysLTs and 
stimulation by ADP 0.1 µM in presence/absence of cangrelor. p=ns (Friedman test) 
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When whole blood was stimulated by an higher concentration of ADP (1 µM) 
with LTC4 (0.8 µM), LTD4 (1 µM), or LTE4 (1.1 µM,) CysLTs had a modulatory 
effect on p-selectin expression, which disappeared in the presence of the P2Y12 
inhibitor cangrelor (FIG 4.9) . However, none of the CysLTs significantly 
affected p-selectin expression induced by ADP. 
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Fig 4.9: Expression of P-selectin in whole blood after treatment with CysLTs and 
stimulation induced by ADP 1 µM in presence/absence of cangrelor.  Data were 
normally distributed; p<0.001 (ANOVA., Bonferroni’s test for internal contrast LTC4 vs 
LTE4 p<0.01 and LTD4 vs LTE4 p<0.001.) 
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5. DISCUSSION AND 
CONCLUSION 
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Platelets play a role in inflammation and CysLTs are important pro-inflammatory 
molecules. It has been hypothesized that some CysLTs may interact with the 
platelet P2Y12 receptor for ADP. However, contrasting results have been 
reported[14, 36, 139, 146]. In our study we tested the effects of CysLTs on 
several tests of platelet function that are dependent on P2Y12 activity. 
Our results indicated that CysLTs alone have no direct effect on platelet 
aggregation in citrate PRP with CysLTs, confirming the findings by Metha et al. 
[147].  
In order to evaluate whether LTC4, LTD4, and LTE4 were able to affect platelet 
aggregation induced by physiological agonists, we tested two concentrations of 
epinephrine and ADP. In contrast with Mehta et al, we were unable to 
demonstrate that CysLTs potentiate the aggregatory effects of these agonists. 
at both tested concentrations (0.1 and 1.0 µM). 
At variance with Mehta et al, we studied the effects of CysLTs on platelet 
aggregation also in hirudin PRP, in which the concentration of plasma Ca2+ is 
maintained at physiological levels. Also under these experimental conditions, 
we were unable to demonstrate any effect of  CysLTs. 
Also when platelet activation was tested by measuring the expression of p-
selectin on the platelet membrane induced by ADP, CysLTs failed to show any 
effect. 
We then focused our studies on the inhibition by ADP of PGE1 induced increase 
in platelet cAMP, a function that is dependent of P2Y12 only. CysLTs had no 
effects also in this platelet function  
Overall, therefore, the results of our studies failed to show any significant effects 
of CysLTs on P2Y12-mediated platelet function, in agreement with some 
previous studies.[146] The negative results of our studies are not due to 
alterations of the CysLTs that we used, as they were identified correctly at mass 
spectrometry and induced normal cellular response of HUVEC, as previously 
shown. 
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The inflammatory effects of CysLTs mediated by the platelet P2Y12 receptor, 
which have been demonstrated in in vivo experiments[14, 36, 139], were most 
likely indirect, rather than induced by a direct interaction of CysLTs with 
platelets. Whether or not this indirect effect is active only in subjects with an 
inflammatory state [8], such as in sensitized mice [3-5] or patients with asthma 
[6] should be studied in properly designed experiments. 
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